| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6818344 | Psychoneuroendocrinology | 2016 | 9 Pages |
Abstract
This study was negative for the primary and secondary clinical outcomes. However, the data suggest a moderate dose of mifepristone may have circumscribed cognitive-enhancing effects in CMI. Further study is warranted to determine whether and through which mechanisms mifepristone treatment can yield clinically meaningful improvement in cognitive function in CMI or other neuropsychiatric conditions associated with HPA axis dysregulation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Julia A. Golier, Kimberly Caramanica, Andreas C. Michaelides, Iouri Makotkine, James Schmeidler, Philip D. Harvey, Rachel Yehuda,